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Abstract
Purpose To assess the effect of different treatment strate-
gies on the risk of subsequent invasive breast cancer (IBC)
in women diagnosed with ductal carcinoma in situ (DCIS).
Methods Up to 15-year cumulative incidences of ipsilat-
eral IBC (iIBC) and contralateral IBC (cIBC) were asses-
sed among a population-based cohort of 10,090 women
treated for DCIS in the Netherlands between 1989 and
2004. Multivariable Cox regression analyses were used to
evaluate associations of treatment with iIBC risk.
Results Fifteen years after DCIS diagnosis, cumulative
incidence of iIBC was 1.9 % after mastectomy, 8.8 % after
BCS?RT, and 15.4 % after BCS alone. Patients treated with
BCS alone had a higher iIBC risk than those treated with
BCS?RT during the first 5 years after treatment. This dif-
ference was less pronounced for patients\50 years [hazard
ratio (HR) 2.11, 95 % confidence interval (CI) 1.35–3.29 for
women\50, and HR 4.44, 95 % CI 3.11–6.36 for
women C50, Pinteraction\ 0.0001]. Beyond 5 years of fol-
low-up, iIBC risk did not differ between patients treated with
BCS?RT or BCS alone for women\50. Cumulative inci-
dence of cIBC at 15 years was 6.4 %, compared to 3.4 % in
the general population.
Conclusions We report an interaction of treatment with age
and follow-up period on iIBC risk, indicating that the benefit of
RT seems to be smaller among younger women, and stressing
the importance of clinical studies with long follow-up. Finally,
the low cIBC risk does not justify contralateral prophylactic
mastectomies for many women with unilateral DCIS.
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cIBC Contralateral invasive breast cancer
DCIS Ductal carcinoma in situ
HR Hazard ratio
IBC Invasive breast cancer
iIBC Ipsilateral invasive breast cancer
NCR Netherlands cancer registry
PALGA Nationwide network and registry of histology
and cytopathology, the Netherlands
RCT Randomized controlled trial
RT Radiotherapy
Introduction
Ductal carcinoma in situ (DCIS) is a potential precursor
lesion of invasive breast cancer (IBC) [1]. Most women
(80–85 %) diagnosed with DCIS present with a
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mammographic abnormality without clinical symptoms
[2]. Since the introduction of population-based mammo-
graphic screening and, more recently, digital mammogra-
phy, the incidence of DCIS has increased substantially
[3–7]. In the Netherlands, the European standardized rate
of in situ breast carcinoma—of which DCIS is the most
common type (*80 %)—increased fivefold since 1989, up
to 25.1 per 100,000 women in 2013 [8]. In the United
States, the incidence (age adjusted to the 2000 US standard
population) increased even more: from 5.8 per 100,000 in
1975 to 33.8 per 100,000 women in 2010 [9].
The natural course of DCIS is not well known because
DCIS has almost always been treated by mastectomy or
breast-conserving surgery (BCS) with or without radio-
therapy (RT). Between 1988 and 2011, only 2 % of women
with DCIS were managed without surgery in the United
States [10]. In the Netherlands, the percentage of non-op-
erated DCIS between 1989 and 2004 was 0.8 % [11].
Women with DCIS are treated to prevent the develop-
ment of IBC, assuming that this may lead to a reduction in
breast cancer-specific deaths. Some women with unilateral
DCIS even undergo contralateral prophylactic mastectomy.
However, the long-term benefit of treating asymptomatic
DCIS that may or may not progress to IBC is difficult to
quantify [12]. Therefore, screening programs are criticized
to be associated with overdiagnosis and resultant
overtreatment of DCIS [13, 14].
Considerable uncertainty remains about the likelihood
that a treatment strategy will prevent IBC, whether that
likelihood will change based on specific patient and DCIS
characteristics, and whether the reduction in risk is enough
to justify the costs and the potential side effects of that
treatment [12]. The effect of different treatment strategies
on the risk of subsequent events in women diagnosed with
DCIS has been addressed previously in both prospective
trials and observational studies [15–27]. However, many of
these studies focused on local recurrences, not discrimi-
nating between invasive and non-invasive events, or did
not have complete information on treatment. Moreover,
several studies have analyzed specific subgroups, such as
‘‘favorable’’ and ‘‘good-risk’’ DCIS, or focused on a
specific treatment strategy.
Gierisch et al. prioritized research needs for DCIS
patients, and pointed out the assessment of the effect of
treatment strategies on IBC, using existing observational
data [12]. We assessed the effect of DCIS treatment
strategies on risk of subsequent ipsilateral invasive breast
cancer (iIBC) using a large population-based cohort with
complete information on treatment and follow-up. In
addition, we analyzed the risk of contralateral IBC (cIBC).
Methods
Patient selection
All women diagnosed with breast carcinoma in situ in the
Netherlands between January 1st 1989 and December 31st
2004 were selected from the Netherlands cancer registry
(NCR) managed by the Netherlands Comprehensive Can-
cer Organization. Patients with previous malignancies,
except for non-melanoma skin cancer, were not included.
This cohort (n = 12,717) was linked to the nationwide
network and registry of histology and cytopathology in the
Netherlands (PALGA) [28]. The selection criteria for this
study were a diagnosis of pure DCIS, i.e., no lobular or
other subtype component, and only treated by surgery with
or without RT. See Fig. 1 for a detailed list of the excluded
cases (n = 2627). The study was approved by the review
boards of the NCR and PALGA.
DCIS treatment and other characteristics
Information on treatment, age, date of diagnosis, and grade
was derived from data provided by NCR. Guidelines for
DCIS treatment in the Netherlands recommend mastec-
tomy or BCS, consisting of microscopic complete tumor
excision. From 1999, the addition of RT after BCS is
included in the recommendation. Adjuvant (hormonal)
treatment is not recommended. Primary DCIS treatment
was categorized into (1) BCS?RT; (2) BCS alone; and (3)
mastectomy. Initial treatment was defined as the final
treatment for the ipsilateral breast within 3 months after
DCIS diagnosis. For patients for whom surgery type was
not coded by NCR, we retrieved this information from
PALGA. We validated whether patients registered by NCR
as treated with BCS had indeed undergone BCS using the
conclusions of pathology reports within 3 months of DCIS
diagnosis. Furthermore, we validated surgical treatment for
women who developed subsequent iIBC after mastectomy,
using conclusion texts of all available pathology reports.
Subsequently, we assessed whether women initially treated
with BCS had undergone ipsilateral mastectomy during
follow-up, using both NCR and PALGA data.
Based on the gradual implementation of the national
breast cancer screening program, we categorized year of
DCIS diagnosis into two periods: 1989–1998 (implemen-
tation phase) and 1999–2004 (full coverage). Age was
subdivided into two groups:\50 and C50 years. Grade
was available for 53 % of the entire cohort. The grading
system used in the Netherlands is based on the classifica-
tion presented by Holland et al. [29].
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Follow-up data
The occurrence of iIBC and cIBC was ascertained based on
NCR data, and additionally, for patients treated with BCS,
through evaluating pathology reports. Follow-up for sub-
sequent IBC and vital status were complete until at least
January 1, 2011.
Statistical analyses
Time at risk started at date of DCIS diagnosis and
stopped at date of diagnosis of the event of interest
(iIBC or cIBC), date of death or emigration, or January
1, 2011, whichever came first. We calculated cumulative
incidence of iIBC and cIBC using death as competing
risk. P values were based on competing risk regression
[30], with time since DCIS diagnosis as time-scale and
adjusted for age (continuous). Further, we compared
cumulative incidence of cIBC with the expected cumu-
lative incidence of IBC in the general population.
Expected cumulative incidence was derived from age-
and period-specific cancer incidence and overall mortal-
ity in the Dutch female population, estimated using the
conditional method [31].
Breast carcinoma in situ
N=12,717
Patients included in the analysis
N=10,090
Excluded (n=2,627)
Diagnosed at autopsy (n=9)
No pure DCIS (n=2,235)
Diagnosed with subsequent IBC within 4 
months after initial DCIS (n=122)
Received chemotherapy and/or hormonal 
therapy for DCIS (n=123)
Not surgically treated or surgery type unknown 
(n=138)
Median follow-up 10.7 years (interquartile 
range 7.7-14.3 years)
Breast conserving surgery alone
N=2,658




Median follow-up (interquartile range)
9.0 (7.1-11.9)
Median follow-up (interquartile range)
12.0 (9.0-15.3)














Fig. 1 Flow diagram for patient selection and median follow-up by initial treatment type. iIBC ipsilateral invasive breast cancer, cIBC
contralateral invasive breast cancer
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Cox proportional hazards analyses, using age as primary
time-scale and time since DCIS diagnosis as secondary
time-scale (0–5, 5–10, and C10 years), were used to
quantify the effects of different treatments on iIBC and
cIBC risks. Period of DCIS diagnosis and age group at
DCIS diagnosis were added as covariables. Proportional
hazard assumptions were verified using graphical and
residual-based methods.
To examine whether iIBC risk differed by grade, we
performed a subgroup analysis for women with a reported
grade. Because the proportion of women with missing data
on grade was more than 30 % up to 1998, we performed
this subgroup analysis for women diagnosed between 1999
and 2004.
Surgical treatment was either analyzed as initial DCIS
treatment (cumulative incidence) or as a time-varying
variable including subsequent mastectomies (Cox regres-
sion analysis).
All statistical analyses were performed using STATA/
SE 13.1 (StataCorp LP, College Station, TX). A two-sided




Analyses included 10,090 women (Fig. 1), of whom 7931
(79 %) women were C50 years at DCIS diagnosis. Median
age at DCIS diagnosis was 57.6 years (interquartile range
50.7–66.3 years). Median follow-up was 10.7 years (in-
terquartile range 7.7–14.3 years). During follow-up, 1856
patients died. Table 1 shows characteristics, events and
follow-up of the study population by treatment group.
DCIS treatment
Nearly 48 % (n = 4820) of DCIS patients were initially
treated with mastectomy. Of all 5270 women initially
treated with BCS, 50 % additionally received RT. Use of
BCS increased over time in women\50 years
(Ptrend = 0.010) and C50 years (Ptrend\ 0.001). The use
of RT after BCS also increased over time in both groups
(Ptrend\ 0.001) (Fig. 2). Fifteen years after initial DCIS
treatment, cumulative incidence of subsequent ipsilateral
mastectomy was 5.2 % in the BCS?RT group, versus
12.0 % in the BCS-alone group.
Ipsilateral invasive breast cancer
During follow-up, 588 women developed an iIBC. The
median time to iIBC was 5.8 years (interquartile range
2.8–9.0 years). Fifteen years after DCIS diagnosis, cumu-
lative incidence of iIBC was 1.9 % [95 % confidence
interval (95 % CI) 1.5–2.4 %] after mastectomy, 8.8 %
(95 % CI 7.1–10.8 %) after BCS?RT, and 15.4 % (95 %
CI 13.9–17.0 %) after BCS alone.
When assessing the risk of iIBC by treatment, the pro-
portional hazards assumption was violated. We accounted
for time dependency in the treatment effect by addition of
an interaction term that involved time and treatment to the
model (Pinteraction\ 0.001). Additionally, we found that
the effect of treatment was different depending on age
group (Pinteraction\ 0.0001). An extra interaction term that
involved period of diagnosis and treatment was not sig-
nificant (Pinteraction = 0.445). Therefore, Table 2 presents
the effect of treatment on iIBC risk by follow-up interval
and age group.
Women diagnosed with DCIS between 1999 and 2004
were less likely to develop iIBC than women diagnosed
between 1989 and 1998, regardless of treatment and age
[hazard ratio (HR) 0.72, 95 % CI 0.59–0.87]. After
adjusting for treatment and period, women C50 years had
lower iIBC risk than\50 women years (HR 0.38, 95 % CI
0.25–0.59). Figure 3 shows the cumulative incidence of
iIBC by treatment strategy stratified by period of DCIS
diagnosis and age group at DCIS diagnosis.
Both women\50 and C50 years treated with BCS
alone had a higher risk of developing iIBC than women
treated with BCS?RT in the first 5 years after DCIS
treatment. However, for women C50 years, the difference
in iIBC risk after BCS alone compared to BCS?RT was
much larger than for women\50 years (HR 2.11, 95 % CI
1.35–3.29 for women\50 years and HR 4.44, 95 % CI
3.11–6.36 for women C50 years). While among
patients\50 years at DCIS diagnosis, risk of iIBC no
longer differed after 5 years following BCS?RT or BCS
alone (HR 1.01, 95 % CI 0.66–1.55 for 5–10 years follow-
up and HR 0.78, 95 % CI 0.46–1.33 for C10 years follow-
up), for women C50 years, iIBC risk remained increased
after BCS alone during subsequent follow-up intervals,
although the difference in risks was smaller than in the first
5 years (HR 1.64, 95 % CI 1.01–2.69 for C10 years fol-
low-up). A trend in the proportional reduction with age was
found when the data were subdivided into three groups
according to age:\45, 45–55, and[55 years (data not
shown).
Women undergoing mastectomy were less likely to
develop iIBC compared to women undergoing BCS
(Table 2). The highest absolute iIBC risk after mastectomy
was seen for women\50 years treated between 1989 and
1998 (10-year cumulative incidence: 2.9 %, 95 % CI
1.9–4.4 %). For women C50 years diagnosed from 1999 to
2004 and treated with mastectomy, the 10-year cumulative
incidence was lowest at 0.6 % (95 % CI 0.2–1.2 %).
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In a subgroup analysis of women diagnosed with
DCIS between 1999 and 2004, the Cox model including
grade was comparable to the main model (data not
shown). The difference in iIBC risk after BCS alone and
BCS?RT was of the same magnitude [e.g., for
women C50 years in the first 5 years after DCIS treat-
ment: HR 4.78, 95 % CI 2.64–8.65 (model including
grade) vs HR 4.57, 95 % CI 2.55–8.22 (main model)].
Additionally, iIBC risk did not differ by grade (adjusted
estimate for intermediate vs low grade and high vs low
grade: HR 1.25, 95 % CI 0.80–1.97 and HR 1.19, 95 %
CI 0.75–1.87, respectively).
Contralateral invasive breast cancer
Contralateral IBC occurred in 536 women. The median
time to cIBC was 6.2 years (interquartile range
3.3–9.8 years). Cumulative incidences of cIBC at 15 and
20 years after DCIS diagnosis were 6.4 % (95 % CI
5.9–7.1 %) and 8.9 % (95 % CI 7.7–10.1 %), respectively,
reaching a rate of 0.4–0.5 % per annum. The risk of cIBC
did not differ by treatment, period of diagnosis, or age
group (see Supplemental Table 1, which demonstrates the
multivariate Cox proportional hazards analysis for cIBC
risk).
Table 1 Characteristics of the study population by treatment group
Number of DCIS patients (%)
Initial DCIS treatment BCS?RT BCS alone Mastectomy Total
Age at DCIS diagnosis, years, median (interquartile range) 57.2 (51.2–65.2) 58.9 (51.2–67.2) 57.1 (49.9–66.5) 57.6 (50.7–66.3)
Age at DCIS diagnosis (years)
\40 91 (3.5) 108 (4.1) 360 (7.5) 559 (5.5)
40–49 367 (14.1) 371 (14.0) 862 (17.9) 1600 (15.9)
50–59 1087 (41.6) 942 (35.4) 1553 (32.2) 3582 (35.5)
60–69 739 (28.3) 785 (29.5) 1245 (25.8) 2769 (27.4)
70–79 308 (11.8) 335 (12.6) 630 (13.1) 630 (13.1)
[80 20 (0.8) 117 (4.4) 170 (3.5) 170 (3.5)
Period of DCIS diagnosis
1989–1998 (implementation phase) 751 (28.8) 1677 (63.1) 2603 (54.0) 5031 (49.9)
1999–2004 (full nationwide coverage) 1861 (71.3) 981 (36.9) 2217 (46.0) 5059 (50.1)
DCIS grade (1999–2004a)
1 215 (13.6) 302 (40.8) 190 (10.2) 707 (16.9)
2 578 (36.7) 235 (31.7) 554 (29.6) 1367 (32.6)
3 783 (49.7) 204 (27.5) 1128 (60.3) 2115 (50.5)
Subsequent ipsilateral mastectomy
No 2497 (95.6) 2345 (88.2) NA 9662 (95.8)
Yes 115 (4.4) 313 (11.8) NA 428 (4.2)
Follow-up interval, years, median (interquartile range) 9.0 (7.1–11.9) 12.0 (9.0–15.3) 11.1 (7.8–14.9) 10.7 (7.7–14.3)
Follow-up interval (years)
0–4b 101 (3.9) 202 (7.6) 301 (6.2) 604 (6.0)
5–9 1458 (55.8) 656 (24.7) 1741 (36.1) 3855 (38.2)
C10 1053 (40.3) 1800 (67.7) 2778 (57.6) 5631 (55.8)
Subsequent invasive breast cancerc
No 2351 (90.0) 2167 (81.5) 4501 (93.4) 9019 (89.4)
Ipsilateral only 130 (5.0) 336 (12.6) 68 (1.4) 534 (5.3)
Contralateral only 122 (4.7) 117 (4.4) 243 (5.0) 482 (4.8)
Ipsilateral?contralateral 9 (0.3) 38 (1.4) 7 (0.15) 54 (0.5)
Total 2612 2658 4820 10090
BCS breast-conserving surgery, RT radiotherapy
a Data on grade is presented for cases diagnosed from 1999. Grade was not reported in 870 women (17.2 %)
b Nine patients with follow-up time = 0 (BCS?RT n = 1, BCS alone n = 2, Mastectomy = 6)
c One patient with unknown laterality of subsequent invasive breast cancer
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The cumulative risk of cIBC is visualized in Fig. 4. The
absolute risk of developing cIBC in women treated for
DCIS was slightly higher than the risk of IBC in the gen-
eral population (3.4 % at 15 years).
Discussion
To the best of our knowledge, this is the largest population-
based, nationwide cohort study with accurate and complete
long-term outcome data of subsequent invasive breast
cancer after DCIS treatment. For women treated with BCS,
our study confirms the protective effect of RT with regard
to iIBC risk shown by randomized controlled trials (RCTs)
[23–27, 32]. Importantly, the benefit of RT regarding iIBC
risk may differ by age and follow-up interval. It appeared
that the use of RT after BCS in women\50 years reduced
the risk of iIBC only in the first years after treatment. In
women C50 years, iIBC risk remained increased during
subsequent follow-up after BCS alone, compared to
BCS?RT, but the difference became less pronounced with
longer follow-up. Our results suggest that RT is effective in
treating microscopic residual disease, but may not prevent
de novo IBC in DCIS patients. One of the RCTs also found
that the beneficial effect of RT seemed to be restricted to
the first 5 years after treatment [24].
Interestingly, the results of our Cox regression analysis
point towards less benefit from RT in women\50 years
than in older women. This observation could be due to
confounding if for example younger women treated with
RT were more likely to have DCIS with unfavorable
prognostic features. However, a meta-analysis of the RCTs
also found age to modify the benefit of RT:
women\50 years showed a smaller proportional risk
reduction in the rate of local recurrence (either in situ or
invasive) than women C50. A trend in the proportional
reduction with age was also found when the data were
subdivided into five age groups and was independent of
histological grade, comedonecrosis, nuclear grade, or
architecture [32].
Additionally, we found high iIBC risks after BCS—ei-
ther with or without RT—in women\50 years. Moreover,
these young women treated with mastectomy had a higher
cumulative iIBC incidence than older women who received
this treatment. Prior studies have also reported that local
recurrences following mastectomy seem to occur particu-
larly in younger women [33–35]. Data that may explain
this higher risk in younger women are limited and incon-
sistent [35–38]. Despite the increased iIBC risk, young age
per se should not be considered a contraindication for BCS,
especially because breast cancer-specific mortality has not
been shown to differ between mastectomy and BCS
[32, 39].
Another clinical relevant observation is that the absolute
risk of cIBC was low with a rate of 0.4–0.5 % per annum.
This result is comparable to the population-based study by
Falk et al. (n = 3,163; median follow-up 5.2 years) [15].
Despite the low cIBC risk, a marked increase in the use of
contralateral prophylactic mastectomies among women
with DCIS in recent years has been reported [40–42].
Because contralateral prophylactic mastectomies will not
likely result in any survival advantage despite the mini-
mization of cIBC risk [43] and are not risk-free [43–45],
we advocate that prophylactic contralateral mastectomies
for DCIS in women without hereditary breast cancer risk
should be discouraged.
One of the strengths of our study was that we differ-
entiated between invasive and non-invasive recurrences.
Our 10-year estimates are in line with the 10-year absolute
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Fig. 2 Treatment strategy by year of diagnosis for
a women\50 years and b women C50 years. BCS breast-conserving
surgery, RT radiotherapy
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RCTs [15, 17, 32]. However, direct comparison with pre-
vious studies, which focused most of their analyses on any
local recurrence as outcome, is often difficult. Differences
in study design, inclusion criteria, and statistical methods
(e.g., cumulative incidence vs Kaplan–Meier estimates)
may for example play a role.
Interestingly, the 10-year cumulative incidence and
Kaplan–Meier estimates in two, rather small, North
American non-randomized prospective studies of women
with ‘‘favorable’’ DCIS treated with BCS alone between
1995 and 2002, were only slightly lower than the 10-year
cumulative incidence of iIBC for women diagnosed
between 1999 and 2004 and treated with BCS alone in our
population-based cohort [21, 22]. On the other hand, the
estimated 7-year iIBC cumulative incidences in a fifth RCT
between BCS?RT (n = 287) and BCS alone (n = 298) in
a selected ‘‘good-risk’’ group of women were much lower
[23]. Notably, in this RCT in which 62 % of women used
tamoxifen, only eight iIBCs occurred in the BCS-alone
arm, and only one in the BCS?RT arm (median follow-up
7.2 years). The differences in risk estimates could be
explained by differences in selection criteria, and utiliza-
tion of tamoxifen, although the effect of tamoxifen on iIBC
seems to be minimal [46].
A limitation of our study is the potential of confounding
by indication. As the allocation of DCIS treatment was not
randomized and the indication for treatment may have been
related to the risk of IBC, this could have introduced bias. It is
plausible to assume that women with less favorable charac-
teristics more often received adjuvant RT after BCS.
Therefore, if confounding by indication plays a role, this will
probably have resulted in an underestimation of the differ-
ence in iIBC risk between BCS?RT and BCS alone.
Although gradewas associatedwith treatment strategy in our
study, we found that grade was not a confounding factor in
our subgroup analysis, as grade was not associated with iIBC
risk. We did not have information on several other risk fac-
tors associated with local recurrence, such as DCIS size and
margin status after excision. However, it is still uncertain to
what extent these factors are associated with subsequent
Table 2 Multivariate Cox regression analysis for iIBC in women treated for DCIS
Age group at DCIS diagnosis Follow-up time Treatment Total iIBC Person-time (years) HR (95 % CI) P value
\50 years 0–5 years BCS?RT 17 2186 Ref
BCS alone 36 2108 2.11 (1.35–3.29) 0.001
Mastectomy 19 6237 0.35 (0.20–0.61) \0.001
5–10 years BCS?RT 19 1579 Ref
BCS alone 23 1668 1.01 (0.66–1.55) 0.95
Mastectomy 12 5414 0.13 (0.07–0.23) \0.001
[10 years BCS?RT 15 808 Ref
BCS alone 20 1346 0.78 (0.46–1.33) 0.37
Mastectomy 11 4455 0.20 (0.11–0.37) \0.001
C50 years 0–5 years BCS?RT 29 10394 Ref
BCS alone 141 9542 4.44 (3.11–6.36) \0.001
Mastectomy 15 18066 0.27 (0.16–0.46) \ 0.001
5–10 years BCS?RT 48 6971 Ref
BCS alone 112 7077 2.13 (1.54–2.96) \0.001
Mastectomy 9 14806 0.10 (0.06–0.17) \0.001
[10 years BCS?RT 11 2353 Ref
BCS alone 40 4391 1.64 (1.01–2.69) 0.05
Mastectomy 11 9515 0.15 (0.08–0.29) \0.001
Period of DCIS diagnosis
1989–1998 412 67011 Ref
1999–2004 176 41906 0.72 (0.59–0.87) 0.03
Age group at DCIS diagnosis
\50 years 172 25801 Ref
C50 years 416 83116 0.38 (0.25–0.59) \0.001
With age as primary time-scale, and treatment as time-varying variable
iIBC ipsilateral invasive breast cancer, HR hazard ratio, CI confidence interval, BCS breast-conserving surgery, RT radiotherapy
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invasive breast cancer risk [47, 48] and therefore whether
these could be confounding factors in our study.
A last issue concerns the applicability of our results to
today’s clinical practice. Our study shows that the risk of
developing iIBC was lower for women diagnosed between
1999 and 2004 than for women diagnosed between 1989
and 1998, while risk of cIBC was similar for both periods.
The decrease in iIBC risk over the years was independent
of treatment strategy and is likely the result of the detection
of relatively more harmless DCIS lesions and improve-
ments in preoperative assessment and surgical
management. Most likely, the risk found for the latter
period reflects the upper boundary of today’s risk of iIBC
in women treated for DCIS, as patient evaluation and
selection for treatment have evolved further since 2004.
It should be emphasized that the women in our cohort
were not treated with tamoxifen for DCIS. In the Nether-
lands, hormonal treatment for DCIS is not recommended
and its use is very limited in current clinical practice
[49, 50]. A meta-analysis of RCTs assessing the effect of
postoperative tamoxifen showed a reduced rate of cIBC,
but no impact on the risk of iIBC or all-cause mortality
a
Overall P <0.0001
BCS alone vs BCS+RT P =0.80
Mastectomy vs BCS+RT P <0.001
b
Overall P<0.0001
BCS alone vs BCS+RT P<0.001
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Fig. 3 Cumulative incidence of iIBC by treatment strategy for
a women\50 years diagnosed between 1989 and 1998
b women C50 years diagnosed between 1989 and 1998
c women\50 years diagnosed between 1999 and 2004
d women C50 years diagnosed between 1999 and 2004, with death
as competing risk. BCS breast-conserving surgery, RT radiotherapy.
P values based on competing risk regression, adjusted for age
(continuous) [30]
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[46]. The difference in absolute IBC risk between our
cohort and a population in which tamoxifen was more
common will therefore probably be limited.
In summary, our finding that the reduction in iIBC risk
among women treated with BCS ? RT, compared to BCS
alone, diminishes with longer follow-up, emphasizes the
importance of clinical studies with long-term follow-up.
Furthermore, the beneficial effect of RT seems to be
smaller among younger women and should be investigated
further. Finally, the low risk of cIBC does not justify
contralateral prophylactic mastectomies for many women
with unilateral DCIS.
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